Daehan New Pharm Co Ltd
KOSDAQ:054670
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Daehan New Pharm Co Ltd
Short-Term Debt
Daehan New Pharm Co Ltd
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Daehan New Pharm Co Ltd
KOSDAQ:054670
|
Short-Term Debt
₩39.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Yuhan Corp
KRX:000100
|
Short-Term Debt
₩199.8B
|
CAGR 3-Years
46%
|
CAGR 5-Years
33%
|
CAGR 10-Years
12%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Short-Term Debt
₩319.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
24%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Short-Term Debt
₩11.8B
|
CAGR 3-Years
62%
|
CAGR 5-Years
42%
|
CAGR 10-Years
10%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Short-Term Debt
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Daehan New Pharm Co Ltd
Glance View
Daehan New Pharm Co., Ltd. engages in the production of pharmaceuticals and animal health goods. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-02-26. The firm provides two categories of products: human pharmaceutical products and animal pharmaceutical products. Its human pharmaceutical products include analgesics, anti-inflammatory drugs, antipyretics, antibacterial, antidiabetics, antihistamines, antineoplastics, immunosuppressants, cardiovascular drugs, gastrointestinal drugs, muscle relaxants, antispasmodics and others. Its animal pharmaceutical products include antibacterial, coccidiostats, antihelmintics, probiotic, nutrients, metabolic stimulants, disinfectants, functional supplement feeds, liver tonics, antihelmintics and others for poultries, cattle, sheep, swine and fishes.
See Also
What is Daehan New Pharm Co Ltd's Short-Term Debt?
Short-Term Debt
39.9B
KRW
Based on the financial report for Dec 31, 2025, Daehan New Pharm Co Ltd's Short-Term Debt amounts to 39.9B KRW.
What is Daehan New Pharm Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 10Y
4%
Over the last year, the Short-Term Debt growth was 1%. The average annual Short-Term Debt growth rates for Daehan New Pharm Co Ltd have been 25% over the past three years , 9% over the past five years , and 4% over the past ten years .
